NRx Pharmaceuticals' stock fell 19.05% in after-hours trading following the announcement of a proposed underwritten public offering of common stock. The company plans to use the proceeds for working capital and general corporate purposes to support growth initiatives. The offering includes a 30-day option for underwriters to buy additional shares, which could dilute existing shareholders. Despite the drop, NRX shares have shown positive price trends over the past year, currently trading below their 52-week high.
Sigenergy has introduced SigenAgent, an AI-driven energy management system designed to optimize solar power, energy storage, and electric vehicle charging. Available globally through the mySigen App 4.0 as a software upgrade, SigenAgent allows users ...
Johnson & Johnson's investigational drug nipocalimab significantly reduced disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) during a Phase 2 study, with effects sustained through 52 weeks. The drug targets pathoge...
SpaceX, led by Elon Musk, is targeting a $75 billion initial public offering (IPO) by selling 555.6 million shares at $135 per share. This move is unusual as the company has set a fixed share price before the typical investor roadshow. The IPO filing...
Bitcoin's fear index, BVIV, surged nearly 20% on June 2, marking its largest single-day increase since February 5. This spike reflects a return of market fear following two months of steady sentiment, triggered by Bitcoin's price dropping over 6% to ...
June is set to be a significant month for mega-cap tech stocks like Nvidia, Apple, Amazon, and Micron, with key events including Nvidia CEO Jensen Huang's keynote at Computex 2026. Investors face a busy schedule filled with AI, semiconductor, and sof...
